Related Experiment Videos
NCAM and lung cancer
R Michalides1, B Kwa, D Springall
1Department of Tumor Biology, The Netherlands Cancer Institute, Amsterdam.
International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement
|January 1, 1994
Summary
Polysialic acid (PSA) on neural cell adhesion molecule (NCAM) correlates with aggressive lung tumors. PSA may impair cell interactions, aiding metastasis, while NCAM antibodies show promise for SCLC imaging and therapy.
Area of Science:
- Oncology
- Neuroscience
- Molecular Biology
Background:
- Neural cell adhesion molecule (NCAM) presence indicates poor prognosis in lung cancer.
- Polysialic acid (PSA) modification of NCAM is explored in neuroendocrine lung tumors.
Purpose of the Study:
- Investigate PSA expression on NCAM in various neuroendocrine lung tumors.
- Correlate PSA presence with tumor aggressiveness and subtype.
- Evaluate NCAM-specific monoclonal antibodies (MAbs) for diagnostic and therapeutic applications.
Main Methods:
- Immunohistochemistry to detect PSA on NCAM in lung tumor tissues.
- In vitro studies to assess the impact of PSA on cell interactions.
- In vivo studies using nude mice xenografts and a SCLC patient for immunoscintigraphy and immunotherapy.
Main Results:
- Significant association found between PSA on tumor cells and aggressive, immature tumor subtypes.
- PSA presence may impair cell-cell and cell-matrix interactions, potentially facilitating metastasis.
- NCAM-MAb 123C3 demonstrated utility in immunoscintigraphy and immunotherapy of SCLC models.
- In vitro studies confirmed internalization of MAb 123C3, a unique characteristic among studied Cluster-I SCLC MAbs.
Conclusions:
- PSA expression on NCAM is a biomarker for aggressive neuroendocrine lung tumors.
- PSA's role in cell adhesion impairment suggests a mechanism for metastasis.
- NCAM-MAb 123C3 holds potential for targeted SCLC diagnostics and therapeutics due to its internalization property.